- As reported by FDA Law Blog, FDA determined on May 7 that Cobalt forfeited its 180-day exclusivity on acarbose and Cobalt sued FDA on May 8 for injunctive relief. Last Friday, for some reason, Cobalt voluntarily dismissed its suit against FDA.
- Also last Friday, FDA appealed the D.C. district court’s decision requiring relisting of Janssen’s patent on Risperdal (risperidone).
- Ivax recently filed a declaratory judgment complaint against AstraZeneca, reportedly seeking to trigger Ranbaxy’s 180-day exclusivity on esomeprazole. AstraZeneca and Ranbaxy settled their esomeprazole litigation last month.
- The district court in Washington, D.C. recently transfered the FTC v. Cephalon "reverse payment" antitrust case to the Eastern District of Pennsylvania, Reuters reported, possibly throwing a wrench into the FTC’s plans to get a "reverse payment" case before the Supreme Court.
- Pharmalot had an interesting post last week on the coming wave of generic drugs from Chinese generic drug companies.
Recent Posts
- Hikma v. Vanda: Oral Argument Recap
- Teva v. Lilly should not be read as creating a new 112 rule for method of use claims
- Should ANDA filers be using the PTAB to mount early challenges to OB patents?
- Switching to WordPress
- Judge Hughes concurrence highlights post grant review appeal standing issue for pharma cases
Posted in 180-Day Exclusivity, Antitrust, Orange Book Issues, Paragraph IV Cases, Pharma Business News
Orange Book Blog 
Leave a comment